TLDR
- Immutep shares plummeted approximately 80% on Friday following the termination of its Phase III lung cancer trial due to futility concerns.
- An IDMC review led to the discontinuation of the TACTI-004 study testing eftilagimod alfa (efti) for first-line non-small cell lung cancer treatment.
- Baird revised its rating from Outperform to Neutral, reducing the price target dramatically from $7.00 down to $1.00.
- Citizens followed suit with a downgrade from Market Outperform to Market Perform, eliminating all NSCLC-related revenue forecasts.
- Share volume skyrocketed past 11 million — dwarfing the typical daily average of approximately 154,000 — as panicked selling intensified.
Shares of Immutep (IMMP) experienced a devastating approximately 80% decline on Friday following the biotech company’s announcement that it would terminate its TACTI-004 Phase III clinical trial. The trial had been testing eftilagimod alfa, commonly referred to as “efti,” as a treatment option for patients diagnosed with first-line non-small cell lung cancer (NSCLC).
The decision to discontinue the study followed a recommendation from the Independent Data Monitoring Committee (IDMC), which conducted a thorough review of both safety and efficacy data. The committee determined the trial should cease due to futility — essentially meaning the available evidence indicated the treatment would not achieve its primary endpoints even if the study proceeded.
Sydney hedge fund Regal was dealt a fresh blow after Immutep, an Australian biotech company it backs, wiped out most of its A$582 million ($412 million) market value on Friday when it halted trials of a lung cancer drug https://t.co/i4XrFFN2cS
— Bloomberg (@business) March 13, 2026
Company CEO Marc Voigt expressed genuine shock at the findings. “We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial,” he stated publicly.
The company confirmed it will immediately stop enrolling new participants and initiate a structured shutdown of the trial, which includes completing patient follow-up procedures and closing out trial sites according to applicable regulatory standards.
Wall Street Responds with Downgrades and Slashed Targets
The financial markets responded immediately — and analyst firms weren’t far behind.
Baird’s equity analyst Colleen Kusy revised her stance on IMMP, downgrading the stock from Outperform to Neutral while simultaneously slashing her price target from $7.00 down to just $1.00. The shares were trading near $2.76 when the downgrade was issued, indicating further downside potential from that level. Baird’s research team indicated they no longer see a viable pathway for efti’s commercial success given these trial results.
Meanwhile, Citizens analyst Reni Benjamin also revised his position, downgrading IMMP from Market Outperform to Market Perform. Benjamin’s updated financial model completely eliminated all revenue assumptions previously attributed to the NSCLC treatment indication.
Both research firms anticipate the stock will likely track broader market movements until the company produces substantial data from its other randomized clinical trials.
Prior to Friday’s devastating news, IMMP stock had been down roughly 3.5% for the year-to-date period, though it had posted gains of 55% over the trailing twelve-month period. Those annual gains have now been virtually wiped out.
The Road Ahead for Immutep
There is one potential positive development for the company: eliminating the TACTI-004 trial removes a substantial financial burden from its books. Immutep now projects its existing cash reserves will last significantly beyond the previously communicated Q2 2027 timeline. The company plans to provide a revised cash runway forecast once it completes the trial shutdown process.
Management indicated it will shift focus toward advancing other pipeline programs. That said, given that NSCLC represented the company’s flagship development program, the future growth trajectory appears substantially more limited.
Friday’s trading activity painted a clear picture of investor sentiment. Trading volume exceeded 11 million shares during the morning session alone — a stark contrast to the three-month daily average of roughly 154,000 shares. This represents approximately 70 times normal trading activity.
The current analyst consensus rating for IMMP stands at Hold, reflecting two Hold ratings. No average price target is available for the stock at present.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
